Pain Cloud® is our B2B platform using the Personalized Analgesics® in-silico network biology research
Traditional R&D
Over-reliance on non-translatable pre-clinical models, and clinical development in market-size determined patient groups that have limited links to the research target, cause the 99% failure rate
Our partnership with Infopoly Ltd.
By partnering with digital technology experts Infopoly Ltd., Pain Cloud® has become an automated platform with the development of a back-end tech stack via integrated novel software.
The network biology algorithm can now be operated, automatically accessing huge data sets from high-quality molecular databases, providing unbiased analysis linking research targets to optimized disease phenotypes.
The cloud based digitalisation enables rapid and precise results with novel software applications providing proprietary data visualizations.
BROAD APPLICATION SPACE ALONG THE VALUE CHAIN
Pain Cloud® uses the Personalized Analgesics® research to match targets and mechanisms with the optimal patient group; e.g., allowing stratification for clinical development.
This significantly de-risks clinical development, as well as enables identifying novel applications for existing medicines, creating market extension and innovative re-purposing opportunities.
ā
Find out more at our Pain Cloud® website
WORKING TOGETHER TO TRANSFORM HOW PAIN IS TREATED
Utilise our novel research techonolgy to increase POS of your R&D projectsā
-
Precisely matching targets to phenotypes;ā
-
Through B2B platform enabled network biology ‘diseasomics’,
-
Developing in stratified patients, selected from >1,000 conditions,
-
Creating flexible partnership structures.
